It’s very generous of Sanolfi-Aventis’s marketing department to make this offer for me to serve as an “advisor” for dronedarone (Multaq), but seriously–I was a bit skeptical that they wanted my “feedback on the reasons for and against utlilization of Multaq® in the appropriate patient as well as to understand communication and educational needs with regard to Multaq® and the atrial fibrillation state in general.”
Where were they when the drug launched? Might it be because this drug hasn’t quite been the blockbuster they’d hoped for?
But, of course, I’d never be swayed to use more of this drug by such important consulting work. No, really.
P.S. Sanolfi-Aventis marketers: Please update your prescriber database with my correct workplace.
-Musings of a cardiologist and cardiac electrophysiologist.
*This blog post was originally published at Dr. Wes*